Literature DB >> 25398203

PCOS in adolescence and type 2 diabetes.

Anne-Marie Carreau1, Jean-Patrice Baillargeon.   

Abstract

Polycystic ovary syndrome is a frequent disorder in women of reproductive age that consists of a heterogeneous combination of hyperandrogenism, chronic anovulation, and polycystic ovaries. Hyperandrogenism and anovulation are clearly linked to insulin resistance and compensatory hyperinsulinism, with an ovarian androgenic hyperresponsiveness to circulating insulin. Evidence is increasing that suggests that lipotoxicity, which is a key mechanism in the development of insulin resistance and type 2 diabetes, could also explain the androgen overproduction. During adolescence, diagnosis of polycystic ovarian syndrome (PCOS) may be difficult but is of importance because PCOS increases future risk of type 2 diabetes and metabolic complications. Metabolic perturbations begin early in adolescence and also exist in adolescent relatives of women with PCOS, even before clinical signs of PCOS. Screening for impaired glucose tolerance or type 2 diabetes is also important in this population, and treatment should focus on PCOS clinical manifestations as well as long-term metabolic risk.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25398203     DOI: 10.1007/s11892-014-0564-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  97 in total

Review 1.  Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.

Authors:  M Costello; B Shrestha; J Eden; P Sjoblom; N Johnson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

3.  Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Authors:  Jean-Patrice Baillargeon; Daniela J Jakubowicz; Maria J Iuorno; Salomon Jakubowicz; John E Nestler
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

4.  Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.

Authors:  Uche Ezeh; Bulent O Yildiz; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

5.  Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002.

Authors:  Stephen Cook; Peggy Auinger; Chaoyang Li; Earl S Ford
Journal:  J Pediatr       Date:  2007-10-22       Impact factor: 4.406

Review 6.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 7.  Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes.

Authors:  André C Carpentier
Journal:  Diabetes Metab       Date:  2008-03-18       Impact factor: 6.041

8.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.

Authors:  M Ashraf Ganie; M L Khurana; M Eunice; N Gupta; M Gulati; S N Dwivedi; A C Ammini
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

9.  Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents.

Authors:  Haleh Rahmanpour; Leila Jamal; Seyed Nouraddin Mousavinasab; Abdolreza Esmailzadeh; Kamran Azarkhish
Journal:  J Pediatr Adolesc Gynecol       Date:  2012-06       Impact factor: 1.814

10.  Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.

Authors:  Catherine C Cowie; Keith F Rust; Earl S Ford; Mark S Eberhardt; Danita D Byrd-Holt; Chaoyang Li; Desmond E Williams; Edward W Gregg; Kathleen E Bainbridge; Sharon H Saydah; Linda S Geiss
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

View more
  11 in total

1.  Serum metabolomics reveals metabolic profiling for women with hyperandrogenism and insulin resistance in polycystic ovary syndrome.

Authors:  Zhihao Zhang; Yanli Hong; Minmin Chen; Ninghua Tan; Shijia Liu; Xiaowei Nie; Wei Zhou
Journal:  Metabolomics       Date:  2020-01-24       Impact factor: 4.290

Review 2.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

3.  Modified Banxia Xiexin Decoction Ameliorates Polycystic Ovarian Syndrome With Insulin Resistance by Regulating Intestinal Microbiota.

Authors:  Hongyu Zhao; Rufeng Chen; Dongxue Zheng; Feng Xiong; Fan Jia; Jinyuan Liu; Lili Zhang; Nana Zhang; Shiqin Zhu; Yongmei Liu; Linhua Zhao; Xinmin Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-05-10       Impact factor: 6.073

4.  Gonadal soma controls ovarian follicle proliferation through Gsdf in zebrafish.

Authors:  Yi-Lin Yan; Thomas Desvignes; Ruth Bremiller; Catherine Wilson; Danielle Dillon; Samantha High; Bruce Draper; Charles Loren Buck; John Postlethwait
Journal:  Dev Dyn       Date:  2017-09-25       Impact factor: 3.780

5.  Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.

Authors:  Vanessa Hoang; Jiangjiang Bi; Sheba M Mohankumar; Arpita K Vyas
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

6.  A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients.

Authors:  Lan Wu; Yazhou Sun; Jun Wan; Ting Luan; Qing Cheng; Yong Tan
Journal:  Mol Med Rep       Date:  2017-05-18       Impact factor: 2.952

7.  Prevalence of Polycystic Ovary Syndrome in Patients With Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis.

Authors:  Milena Cioana; Jiawen Deng; Ajantha Nadarajah; Maggie Hou; Yuan Qiu; Sondra Song Jie Chen; Angelica Rivas; Laura Banfield; Haifa Alfaraidi; Ahlam Alotaibi; Lehana Thabane; M Constantine Samaan
Journal:  JAMA Netw Open       Date:  2022-02-01

8.  The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review

Authors:  Elif Günalan; Aylin Yaba; Bayram Yılmaz
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-10-09

9.  Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome.

Authors:  Ling Zhou; Zhexin Ni; Jin Yu; Wen Cheng; Zailong Cai; Chaoqin Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-08       Impact factor: 5.555

Review 10.  Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility.

Authors:  Valeria Calcaterra; Elvira Verduci; Hellas Cena; Vittoria Carlotta Magenes; Carolina Federica Todisco; Elisavietta Tenuta; Cristina Gregorio; Rachele De Giuseppe; Alessandra Bosetti; Elisabetta Di Profio; Gianvincenzo Zuccotti
Journal:  Nutrients       Date:  2021-05-28       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.